These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
96 related articles for article (PubMed ID: 8875750)
1. Radioiodine treatment of thyroid carcinoma in patients on maintenance hemodialysis. Daumerie C; Vynckier S; Caussin J; Jadoul M; Squifflet JP; de Patoul N; Wambersie A Thyroid; 1996 Aug; 6(4):301-4. PubMed ID: 8875750 [TBL] [Abstract][Full Text] [Related]
2. Management of thyroid papillary carcinoma with radioiodine in a patient with end stage renal disease on hemodialysis. Mello AM; Isaacs R; Petersen J; Kronenberger S; McDougall IR Clin Nucl Med; 1994 Sep; 19(9):776-81. PubMed ID: 7982310 [TBL] [Abstract][Full Text] [Related]
3. Iodine-131 treatment of thyroid papillary carcinoma in patients undergoing dialysis for chronic renal failure: a dosimetric method. Jiménez RG; Moreno AS; Gonzalez EN; Simón FJL ; Rodriguez JR; Jimenez JC; Córdoba MH; Albertino RV; Jimenez RA Thyroid; 2001 Nov; 11(11):1031-4. PubMed ID: 11762712 [TBL] [Abstract][Full Text] [Related]
4. Radiation safety protocol for high dose 131I therapy of thyroid carcinoma in patients on hemodialysis for chronic renal failure. Modarresifar H; Almodovar S; Bass WB; Ojha B Health Phys; 2007 Feb; 92(2 Suppl):S45-9. PubMed ID: 17228187 [TBL] [Abstract][Full Text] [Related]
5. Iodine 131 ablation therapy for a patient on maintenance haemodialysis. Howard N; Glasser M Br J Radiol; 1981 Mar; 54(639):259. PubMed ID: 7470791 [No Abstract] [Full Text] [Related]
6. The management of well-differentiated thyroid cancer with end-stage renal disease. Wang TH; Lee CH; Tseng LM; Liu RH Endocrine; 2003 Aug; 21(3):227-31. PubMed ID: 14515006 [TBL] [Abstract][Full Text] [Related]
7. Effects of hemodialysis on iodine-131 biokinetics in thyroid carcinoma patients with end-stage chronic renal failure. Yeyin N; Cavdar I; Uslu L; Abuqbeitah M; Demir M Nucl Med Commun; 2016 Mar; 37(3):283-7. PubMed ID: 26619394 [TBL] [Abstract][Full Text] [Related]
8. [Treatment with (131)I of thyroid remnants in a patient with papillary thyroid carcinoma and end-stage chronic renal failure]. Andres A; Tardín L; Santapau A; Razola P; Prats E; Parra A; Rivas MA; Ruiz P; Alvarez R; Camara A; Banzo J Rev Esp Med Nucl; 2010; 29(1):32-5. PubMed ID: 20018412 [TBL] [Abstract][Full Text] [Related]
9. 131I treatment of thyroid papillary carcinoma in a patient with renal failure. Morrish DW; Filipow LJ; McEwan AJ; Schmidt R; Murland KR; von Westarp C; Betcher KB Cancer; 1990 Dec; 66(12):2509-13. PubMed ID: 2249192 [TBL] [Abstract][Full Text] [Related]
10. (131)I treatment in Differentiated Thyroid Cancer and End-Stage Renal Disease. Ortega AJ; Vázquez RG; Cuenca JI; Brocca MA; Castilla J; Martínez JM; González EN Rev Esp Med Nucl Imagen Mol; 2016; 35(1):29-33. PubMed ID: 26144699 [TBL] [Abstract][Full Text] [Related]
12. Radioiodine dosimetry in patients with end-stage renal disease receiving continuous ambulatory peritoneal dialysis therapy. Kaptein EM; Levenson H; Siegel ME; Gadallah M; Akmal M J Clin Endocrinol Metab; 2000 Sep; 85(9):3058-64. PubMed ID: 10999786 [TBL] [Abstract][Full Text] [Related]
13. One size does not fit all: the merit of absorbed doses to the blood in 131I therapy for differentiated thyroid carcinoma. Fatholahi L; Tabeie F; Pashazadeh AM; Javadi H; Assadi M; Asli IN Health Phys; 2015 Jan; 108(1):53-8. PubMed ID: 25437520 [TBL] [Abstract][Full Text] [Related]
14. Disposition of radioiodine (131)I therapy for thyroid carcinoma in a patient with severely impaired renal function on chronic dialysis: a case report. Magné N; Magné J; Bracco J; Bussière F Jpn J Clin Oncol; 2002 Jun; 32(6):202-5. PubMed ID: 12110636 [TBL] [Abstract][Full Text] [Related]
15. Hemodialysis in patients requiring 131I treatment for thyroid carcinoma. Fofi C; Festuccia F; Barberi S; Apponi F; Chiacchiararelli L; Scopinaro F; Punzo G; Menè P Int J Artif Organs; 2013 Jun; 36(6):439-43. PubMed ID: 23653300 [TBL] [Abstract][Full Text] [Related]
16. [Necessity to administer 131I in a patient with papillary thyroid carcinoma undergoing chronic hemodialysis]. Novik V; González R; Díaz M; Vega J Rev Med Chil; 1998 Jul; 126(7):874-5. PubMed ID: 9830782 [No Abstract] [Full Text] [Related]
17. A case of stunning of lung and bone metastases of papillary thyroid cancer after a therapeutic dose (3.7 GBq) of 131I and review of the literature: implications for sequential treatments. Leger AF; Pellan M; Dagousset F; Chevalier A; Keller I; Clerc J Br J Radiol; 2005 May; 78(929):428-32. PubMed ID: 15845937 [TBL] [Abstract][Full Text] [Related]
18. The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma. Tsang RW; Brierley JD; Simpson WJ; Panzarella T; Gospodarowicz MK; Sutcliffe SB Cancer; 1998 Jan; 82(2):375-88. PubMed ID: 9445196 [TBL] [Abstract][Full Text] [Related]
19. Radioactive 131I use in end-stage renal disease: nightmare or nuisance? Sinsakul M; Ali A Semin Dial; 2004; 17(1):53-6. PubMed ID: 14717812 [TBL] [Abstract][Full Text] [Related]
20. Use of radioactive iodine I-131 and monitoring of radioactivity in patients with chronic kidney disease on haemodialysis. Gallegos-Villalobos A; García-López F; Escalada C; Ortiz JJ; Cardona J; Medina A; Portolés J Nefrologia; 2014 May; 34(3):317-22. PubMed ID: 24798564 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]